Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates.

[1]  Nikolaus R. McFarland,et al.  Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system , 2009, Journal of neurochemistry.

[2]  B. Davidson,et al.  Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. , 2008, Human gene therapy.

[3]  James M. Wilson,et al.  Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  M. Souweidane,et al.  Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. , 2008, Human gene therapy.

[5]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[6]  J. L. Eberling,et al.  Results from a phase I safety trial of hAADC gene therapy for Parkinson disease , 2008, Neurology.

[7]  R. Bakay,et al.  Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial , 2008, The Lancet Neurology.

[8]  D. Kirik,et al.  In vivo gene delivery for development of mammalian models for Parkinson's disease , 2008, Experimental Neurology.

[9]  C. Olanow,et al.  Regulatable promoters and gene therapy for Parkinson's disease: Is the only thing to fear, fear itself? , 2008, Experimental Neurology.

[10]  T. Flotte,et al.  Recombinant adeno-associated virus-mediated global anterograde delivery of glial cell line-derived neurotrophic factor to the spinal cord: comparison of rubrospinal and corticospinal tracts in the rat. , 2008, Human gene therapy.

[11]  R. Mandel,et al.  Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  David Eidelberg,et al.  Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.

[13]  D. Murphy,et al.  Altered neocortical cell density and layer thickness in serotonin transporter knockout mice: a quantitation study. , 2007, Cerebral cortex.

[14]  Zeger Debyser,et al.  Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. , 2007, Human gene therapy.

[15]  B. Hyman,et al.  Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain , 2006, Neuroscience.

[16]  R. Bakay,et al.  Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys , 2006, Annals of neurology.

[17]  D. Shera,et al.  Immune responses to AAV in a phase I study for Canavan disease , 2006, The journal of gene medicine.

[18]  J. Bringas,et al.  Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. , 2006, Human gene therapy.

[19]  Ronald L Klein,et al.  Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  P. R. Hof,et al.  Design-based stereology in neuroscience , 2005, Neuroscience.

[21]  Brian M. Suzuki,et al.  AAV2-mediated gene delivery to monkey putamen: Evaluation of an infusion device and delivery parameters , 2005, Experimental Neurology.

[22]  R. Mandel,et al.  Recombinant adeno-associated viral vectors in the nervous system. , 2005, Human gene therapy.

[23]  James M. Wilson,et al.  New recombinant serotypes of AAV vectors. , 2005, Current gene therapy.

[24]  R. Mandel,et al.  Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  T. Iwatsubo,et al.  Overexpression of α‐synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α‐synuclein and activation of caspase‐9: resemblance to pathogenetic changes in Parkinson's disease , 2004, Journal of neurochemistry.

[26]  P. Reier,et al.  Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  J. Feldon,et al.  Transduction Profiles of Recombinant Adeno-Associated Virus Vectors Derived from Serotypes 2 and 5 in the Nigrostriatal System of Rats , 2004, Journal of Virology.

[28]  R. Mandel,et al.  Circulating Anti-Wild-Type Adeno-Associated Virus Type 2 (AAV2) Antibodies Inhibit Recombinant AAV2 (rAAV2)-Mediated, but Not rAAV5-Mediated, Gene Transfer in the Brain , 2004, Journal of Virology.

[29]  M. Hildinger,et al.  Advances in AAV-mediated gene transfer for the treatment of inherited disorders , 2004, European Journal of Human Genetics.

[30]  C. Vite,et al.  Adeno-associated virus vector-mediated transduction in the cat brain , 2003, Gene Therapy.

[31]  Anders Björklund,et al.  Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors , 2003, Trends in Neurosciences.

[32]  S. Leurgans,et al.  Structural and functional neuroprotection in a rat model of Huntington’s disease by viral gene transfer of GDNF , 2003, Experimental Neurology.

[33]  A. Björklund,et al.  Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Hauswirth,et al.  Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. , 2002, Methods.

[35]  Zeger Debyser,et al.  Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. , 2002, Human gene therapy.

[36]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[37]  Ronald L Klein,et al.  Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. , 2002, Human gene therapy.

[38]  M. Dragunow,et al.  Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes , 2001, Gene Therapy.

[39]  I. Martins,et al.  Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Schlehofer,et al.  Update on the prevalence of serum antibodies (IgG and IgM) to adeno‐associated virus (AAV) , 1999, Journal of medical virology.

[41]  J. Bloch,et al.  Lentiviral Gene Transfer to the Nonhuman Primate Brain , 1999, Experimental Neurology.

[42]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[43]  J. Holden,et al.  Age‐related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys , 1998, The Journal of comparative neurology.

[44]  R. Samulski,et al.  Selective and rapid uptake of adeno-associated virus type 2 in brain. , 1998, Human gene therapy.

[45]  W. Hauswirth,et al.  A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells , 1996, Journal of virology.

[46]  N. Muzyczka.  Use of adeno-associated virus as a general transduction vector for mammalian cells. , 1992, Current topics in microbiology and immunology.

[47]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[48]  H. Niwa,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.